Seven members of the PTC Therapeutics team joined 11 HD-CAB team members for an advisory board on the 3rd November. Sian O’Neill, Senior Director of Patient Engagement EMEA & AP wrote following the meeting to say “Thank you again for the opportunity to participate in the 1st HD-CAB. It was a pleasure to meet such an amazing group of people. The CAB team has pushed the PTC team into overdrive! The real and honest sharing of the reality of HD has generated a lot of questions and dare I say shifted the thought process for our team.”
News
Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease
PROOF-HD is the only late-stage study in Huntington’s disease targeting clinical progression; topline results expected in early Q2 2023 NAARDEN, Netherlands and WALTHAM, Mass., 28 March 2023 – Prilenia Therapeutics B.V., a clinical stage biotechnology company focused Read more…